Australia-based Telix Pharmaceuticals has agreed to acquire Germany’s ITM Isotope Technologies Munich in a transaction valued at $1.65 billion upfront, adding a late-stage radiopharmaceutical candidate, manufacturing infrastructure and a distribution network covering more than 65 countries.
The deal also includes up to $700 million in milestone payments linked primarily to regulatory approvals and commercial performance of ITM-11, a lutetium-177-based radioligand therapy being developed for neuroendocrine tumors. Telix will additionally assume more than $300 million in ITM debt at closing. The companies expect the acquisition to be completed by the end of the year.
ITM-11 Included in Acquisition Agreement
The transaction brings ITM-11 into Telix’s portfolio. The radiopharmaceutical targets the somatostatin receptor and is being developed for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Last month, the U.S. Food and Drug Administration rejected the therapy’s application. According to ITM, the FDA cited chemistry, manufacturing, and controls issues as well as findings identified during an inspection of a third-party commercial facility. The company said no clinical safety or efficacy concerns were identified.
ITM is reviewing the agency’s feedback and working with external partners to address the issues. The company plans to resubmit its application, although the timing will depend on remediation efforts and discussions with the FDA. Resubmission of the application, or an agreement between Telix and ITM on the path forward, is among the conditions for completing the acquisition.
Telix Chief Executive Officer Christian Behrenbruch expressed confidence in the process, stating: “We know this third-party facility very well, and the broader regulatory context.”
Milestone Payments Linked to Future Approvals
Several of the transaction’s milestone payments are tied to ITM-11. Telix could pay $100 million if the therapy receives FDA approval for a GEP-NET indication by the end of next year, and another $100 million if it gains approval in an additional GEP-NET indication by the end of 2030.
An additional $50 million payment is tied to a potential approval in lung neuroendocrine tumors by the end of 2031. Beyond regulatory milestones, up to $450 million more could be paid based on sales performance.
ITM-11 is also being developed for lung and thymic neuroendocrine tumors. The investigator-initiated Phase 3 LEVEL study is currently recruiting participants, with topline data expected in 2029.
Manufacturing Network and Combined Company Plans
The acquisition adds ITM’s manufacturing infrastructure and distribution network to Telix. ITM reported $273 million in sales in 2025 and supplies lutetium-177, an isotope used in radiopharmaceutical products including Novartis’ Pluvicto. The isotope is also used in Lutathera, ITM-11 and Telix’s TLX591.
William Blair analysts described the acquisition as “supercritical” and wrote that they were highly optimistic about the future growth prospects of the combined company. The analysts cited opportunities related to manufacturing, vertical integration, and the addition of research and development assets, including ITM-11.
Following completion of the transaction, Telix shareholders are expected to own approximately 76.3% of the combined company, while ITM investors will hold about 23.7%.
Telix said the merged organization is expected to generate more than $1.3 billion in unaudited revenue and income this year. The company currently markets radioisotopes for imaging prostate and brain cancer and is developing radioligand therapies, including the Phase 3 candidate TLX591.
Market Impact of the Acquisition
The proposed $1.65 billion transaction would give the combined company a broader presence across the radiopharmaceutical value chain. ITM brings specialized isotope production capabilities, while the acquiring company contributes an established commercial infrastructure and experience in developing and distributing molecularly targeted imaging and therapeutic products.
Focus on ITM-11
ITM-11 is one of the most important assets involved in the transaction. The investigational therapy uses lutetium-177 to target somatostatin receptor-positive tumors, with development focused on gastroenteropancreatic neuroendocrine tumors. Its late-stage development status makes it a potentially important addition to the buyer’s oncology pipeline.
Additional clinical and regulatory milestones will determine how quickly the therapy could progress toward commercialization. The program’s future development will remain dependent on clinical evidence and regulatory review.
Strengthening Radioisotope Supply
One of the strategic attractions of the transaction is ITM’s radioisotope manufacturing infrastructure. Reliable access to medical radioisotopes is increasingly important as targeted radionuclide therapies move through clinical development and into commercial use.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
